Atenolol
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Beta Blockers | Atenolol | 25 mg PO Q24H | Administer Post HD session |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 266 | 85 | 6-7 | 15-35 | 6-16 | 1.1 | 42.6 | 75 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00335
- Flouvat B, Decourt S, Aubert P, et al. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. British journal of clinical pharmacology. 1980;9(4):379-85.
- Inrig JK. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.